|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.26 EUR | +0.15% |
|
+0.54% | -42.73% |
| 12-03 | BAYER AG : JP Morgan reaffirms its Neutral rating | ZD |
| 12-03 | ZBD Pharma Gets China Approval for Antibacterial Injection | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Capitalization | 18.9B 19.86B 17.6B 15.69B 27.94B 1,683B 30.68B 219B 81.14B 690B 74.63B 72.96B 2,970B | P/E ratio 2024 * |
-695x | P/E ratio 2025 * | 8.1x |
|---|---|---|---|---|---|
| Enterprise value | 51.21B 53.83B 47.7B 42.52B 75.72B 4,560B 83.13B 593B 220B 1,870B 202B 198B 8,048B | EV / Sales 2024 * |
1.1x | EV / Sales 2025 * | 1.03x |
| Free-Float |
100% | Yield 2024 * |
0.57% | Yield 2025 * | 0.57% |
More valuation ratios
* Estimated data
More news
Last Transcript: Bayer AG
More press releases
More news
| 1 day | +0.01% | ||
| 1 week | +0.35% | ||
| Current month | -0.85% | ||
| 1 month | -22.31% | ||
| 3 months | -31.07% | ||
| 6 months | -32.15% | ||
| Current year | -42.84% |
1 week
18.93
19.52
1 month
18.4125.24
Current year
18.4136.09
1 year
18.4136.09
3 years
18.4167.99
5 years
18.4178.34
10 years
18.41146.45
| Director | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 58 | 31/05/2023 |
| Director of Finance/CFO | 55 | 31/05/2018 | |
Christian Rommel
CTO | Chief Tech/Sci/R&D Officer | 57 | 31/01/2021 |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Achleitner
BRD | Director/Board Member | 68 | 31/03/2002 |
André van Broich
BRD | Director/Board Member | 54 | 31/03/2012 |
| Director/Board Member | 65 | 31/03/2022 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.77% | 70 M€ | -.--% | ||
| 5.71% | 2 M€ | +13.56% | - | |
| 4.28% | 962 M€ | -.--% | - | |
| 4.10% | 0 M€ | +56.26% | - | |
| 4.10% | 0 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.01% | +0.35% | -37.64% | -56.88% | 19.86B | ||
| +1.69% | +3.04% | +39.26% | +231.19% | 732B | ||
| -0.81% | +4.84% | +12.60% | +119.98% | 488B | ||
| -1.58% | -1.40% | -3.80% | -4.40% | 367B | ||
| -0.15% | +0.20% | +26.56% | +52.71% | 321B | ||
| +1.23% | +0.23% | -1.56% | +38.87% | 258B | ||
| -0.29% | +0.51% | +3.05% | -30.95% | 231B | ||
| -2.12% | -1.75% | +5.79% | +22.11% | 210B | ||
| -2.60% | -0.06% | +2.53% | +25.86% | 212B | ||
| +0.08% | -0.60% | +2.15% | +37.48% | 150B | ||
| Average | -0.48% | +0.68% | +4.89% | +43.60% | 298.69B | |
| Weighted average by Cap. | -0.42% | +1.24% | +14.61% | +87.24% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 46.41B 48.79B 43.23B 38.53B 68.63B 4,133B 75.35B 537B 199B 1,695B 183B 179B 7,294B | 46.62B 49.01B 43.43B 38.71B 68.94B 4,151B 75.69B 540B 200B 1,702B 184B 180B 7,327B |
| Net income | -25.93M -27.26M -24.15M -21.53M -38.35M -2.31B -42.1M -300M -111M -947M -102M -100M -4.08B | 2.33B 2.45B 2.17B 1.94B 3.45B 208B 3.79B 27.03B 10.02B 85.23B 9.22B 9.01B 367B |
| Net Debt | 32.31B 33.96B 30.1B 26.83B 47.78B 2,877B 52.45B 374B 139B 1,180B 128B 125B 5,078B | 29.31B 30.81B 27.3B 24.33B 43.34B 2,610B 47.58B 339B 126B 1,070B 116B 113B 4,606B |
More financial data
* Estimated data
Employees
94,245
Sector
Pharmaceuticals
Calendar
03/12/2024
- Citi Global Healthcare Conference
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/12/24 | 19.26 € | +0.14% | 978,414 |
| 03/12/24 | 19.23 € | -0.27% | 2,918,759 |
| 02/12/24 | 19.29 € | -0.53% | 4,490,618 |
| 29/11/24 | 19.39 € | +0.11% | 3,603,253 |
| 28/11/24 | 19.37 € | +1.10% | 3,236,745 |
Delayed Quote Xetra, December 04, 2024 at 10:46 am
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
19.23EUR
Average target price
28.16EUR
Spread / Average Target
+46.38%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAYN Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition